Date: 2013-09-16
Type of information: Licensing agreement
Compound: CRISPR gene editing technology
Company: Horizon Discovery (UK) Harvard University (USA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: CRISPR is an RNA-guided gene editing system which gained notoriety in late 2012 through the simultaneous publication of several seminal articles describing its ability to introduce either a targeted double strand break or single strand nick in the genome of mammalian cells.
Disease:
Details: * On September 16, 2013, Horizon Discovery, a UK provider of research tools to support translational genomics research and the development of personalized medicines, has announced it has entered into a non-exclusive license agreement with Harvard University to access intellectual property related to the commercialization of CRISPR gene editing technology for research use. This agreement allows Horizon to add CRISPR to its GENESIS™ precision gene-editing platform and to provide an expanded toolbox to perform rapid functional genomics experiments for deployment at all stages of drug discovery and diagnostic development. Horizon will employ all three genome editing technologies for custom client-led projects, as well as to expand on its own menu of over 500 genetically-defined off-the-shelf cell lines and related products. In addition, the company will soon launch a range of rAAV, CRISPR and hybrid rAAV/CRISPR gene-editing kits and associated reagents, supported by Horizon’s technical team with expertise in all gene editing platforms and their application in translational research.
Financial terms:
Latest news:
